{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"145"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"145"}],"units":"Participants"}],"description":"return to ANC (absolute neutrophil count) more than 500 cells/milliliter.","groups":[{"description":"Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.","id":"OG000","title":"NHL With Irradiation"},{"description":"Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.","id":"OG001","title":"HL Without Irradiation"},{"description":"Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.","id":"OG002","title":"NHL - HIV Infected With Irradiation"},{"description":"Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.","id":"OG003","title":"NHL - HIV Infected Without Irradiation"},{"description":"Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).","id":"OG004","title":"NHL Without Radiation and Cyclophosphamide"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 42","title":"Number of Participants With Hematopoietic Recovery After Transplantation","type":"SECONDARY","unitOfMeasure":"Participants"}